Trial · NCT03278106
Adverse events50
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 50
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neutrophil count decreased | Investigations | Treatment (TAS-102) | 15 | 27 | 38 |
| other | Platelet count decreased | Investigations | Treatment (TAS-102) | 16 | 27 | 38 |
| other | White blood cell decreased | Investigations | Treatment (TAS-102) | 12 | 27 | 20 |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (TAS-102) | 20 | 27 | 54 |
| other | Hypoalbuminemia | Metabolism and nutrition disorders | Treatment (TAS-102) | 1 | 27 | 2 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Treatment (TAS-102) | 2 | 27 | 9 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Treatment (TAS-102) | 4 | 27 | 6 |
| other | Generalized muscle weakness | Musculoskeletal and connective tissue disorders | Treatment (TAS-102) | 2 | 27 | 2 |
| other | Pain in extremity | Musculoskeletal and connective tissue disorders | Treatment (TAS-102) | 1 | 27 | 2 |
| other | Tumor pain | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Treatment (TAS-102) | 1 | 27 | 2 |
| other | Headache | Nervous system disorders | Treatment (TAS-102) | 1 | 27 | 8 |
| other | Peripheral sensory neuropathy | Nervous system disorders | Treatment (TAS-102) | 3 | 27 | 6 |
| other | Confusion | Psychiatric disorders | Treatment (TAS-102) | 1 | 27 | 1 |
| other | Insomnia | Psychiatric disorders | Treatment (TAS-102) | 1 | 27 | 4 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Treatment (TAS-102) | 2 | 27 | 4 |
| other | Alopecia | Skin and subcutaneous tissue disorders | Treatment (TAS-102) | 2 | 27 | 2 |
| other | Pruritus | Skin and subcutaneous tissue disorders | Treatment (TAS-102) | 1 | 27 | 1 |
| other | Skin and subcutaneous tissue disorders - Other, specify | Skin and subcutaneous tissue disorders | Treatment (TAS-102) | 1 | 27 | 2 |
| other | Hypertension | Vascular disorders | Treatment (TAS-102) | 2 | 27 | 4 |
| serious | Anemia | Blood and lymphatic system disorders | Treatment (TAS-102) | 2 | 27 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03278106/events?page=2